The Biologics News and Reports Portal

Show Cart

All Products

Results 121 - 140 of 171

Jun 2013 Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares

2,150.00 €

Jun 2013 Competitor Analysis: Anthrax Vaccines & Therapeutics

200.00 €

May 2013 Competitor Analysis: Human Papilloma Virus (HPV) Vaccines & Therapeutics

250.00 €

May 2013 Flat-Rate Subscription to La Merie Publishing Reports

4,000.00 €

May 2013 Competitor Analysis: Thrombolytics & Fibrinolytics

250.00 €

May 2013 Competitor Analysis: Coagulation Factors

600.00 €

May 2013 Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

1,600.00 €

Apr 2013 Competitor Analysis: Insulin

450.00 €

Apr 2013 Competitor Analysis: Interferon

450.00 €

Apr 2013 Competitor Analysis: Thrombopoiesis Stimulating Agents (TPO and IL-11)

150.00 €

Apr 2013 Competitor Analysis: Human Growth Hormone (hGH)

300.00 €

Apr 2013 Competitor Analysis: Erythropoiesis Stimulating Agents (ESA)

500.00 €

Mar 2013 Antibody Technologies and Attrition Rates – an industry analysis 2013

2,150.00 €

Mar 2013 Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis

900.00 €

Shopping cart

Cart empty

Latest report

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Latest Target Pipeline

Asparagine Depleting Therapies

Shopping cart

Cart empty

Latest report

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

All Products

Aug 2013 Competitor Analysis: Focal Adhesion Kinase (FAK) Inhibitors

Aug 2013 Competitor Analysis: Anaplastic Lymphoma Kinase (ALK) Inhibitors

Aug 2013 Competitor Analysis: Smallpox Vaccines & Therapeutics

Aug 2013 Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors

Jul 2013 Competitor Analysis ErbB / Her Receptor Antagonists

Jul 2013 Competitor Analysis: c-MET/HGF Inhibitors

Jun 2013 Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares

Jun 2013 Competitor Analysis: Anthrax Vaccines & Therapeutics

May 2013 Competitor Analysis: Human Papilloma Virus (HPV) Vaccines & Therapeutics

May 2013 Flat-Rate Subscription to La Merie Publishing Reports

May 2013 Competitor Analysis: Thrombolytics & Fibrinolytics

May 2013 Competitor Analysis: Coagulation Factors

May 2013 Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

Apr 2013 Competitor Analysis: Insulin

Apr 2013 Competitor Analysis: Interferon

Apr 2013 Competitor Analysis: Thrombopoiesis Stimulating Agents (TPO and IL-11)

Apr 2013 Competitor Analysis: Human Growth Hormone (hGH)

Apr 2013 Competitor Analysis: Erythropoiesis Stimulating Agents (ESA)

Mar 2013 Antibody Technologies and Attrition Rates – an industry analysis 2013

Mar 2013 Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing